Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Chemotherapy followed by syngeneic dendritic cell injection in the mouse: findings and implications for human treatment.

Cavanagh WA, Tjoa BA, Ragde H.

Urology. 2007 Dec;70(6 Suppl):36-41. doi: 10.1016/j.urology.2007.06.1127. Review.

PMID:
18194710
2.

Dendritic cell based vaccines: progress in immunotherapy studies for prostate cancer.

Ragde H, Cavanagh WA, Tjoa BA.

J Urol. 2004 Dec;172(6 Pt 2):2532-8. Review.

PMID:
15538202
3.

Dendritic cell-based immunotherapy for prostate cancer.

Tjoa BA, Lodge PA, Salgaller ML, Boynton AL, Murphy GP.

CA Cancer J Clin. 1999 Mar-Apr;49(2):117-28, 65.

4.

Progress in active-specific immunotherapy of brain malignancies.

Tjoa BA, Salgaller ML.

Expert Opin Investig Drugs. 2000 Sep;9(9):2093-101. Review.

PMID:
11060795
5.

Development of dendritic-cell based prostate cancer vaccine.

Tjoa BA, Murphy GP.

Immunol Lett. 2000 Sep 15;74(1):87-93. Review.

PMID:
10996633
6.

Higher-dose and less frequent dendritic cell infusions with PSMA peptides in hormone-refractory metastatic prostate cancer patients.

Murphy GP, Tjoa BA, Simmons SJ, Rogers MK, Kenny GM, Jarisch J.

Prostate. 2000 Apr 1;43(1):59-62.

PMID:
10725866
7.

Progress in active specific immunotherapy of prostate cancer.

Tjoa BA, Murphy GP.

Semin Surg Oncol. 2000 Jan-Feb;18(1):80-7. Review.

PMID:
10617899
8.

Use of artificial neural networks in evaluating prognostic factors determining the response to dendritic cells pulsed with PSMA peptides in prostate cancer patients.

Murphy GP, Snow P, Simmons SJ, Tjoa BA, Rogers MK, Brandt J, Healy CG, Bolton WE, Rodbold D.

Prostate. 2000 Jan;42(1):67-72.

PMID:
10579800
9.

Follow-up evaluation of a phase II prostate cancer vaccine trial.

Tjoa BA, Simmons SJ, Elgamal A, Rogers M, Ragde H, Kenny GM, Troychak MJ, Boynton AL, Murphy GP.

Prostate. 1999 Jul 1;40(2):125-9.

PMID:
10386473
10.

Vaccine therapy for prostate cancer.

Tjoa BA, Elgamal AA, Murphy GP.

Urol Clin North Am. 1999 May;26(2):365-74, ix.

PMID:
10361559
11.

GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial.

Simmons SJ, Tjoa BA, Rogers M, Elgamal A, Kenny GM, Ragde H, Troychak MJ, Boynton AL, Murphy GP.

Prostate. 1999 Jun 1;39(4):291-7.

PMID:
10344219
12.

Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment.

Murphy GP, Tjoa BA, Simmons SJ, Ragde H, Rogers M, Elgamal A, Kenny GM, Troychak MJ, Salgaller ML, Boynton AL.

Prostate. 1999 Apr 1;39(1):54-9.

PMID:
10221267
13.

Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease.

Murphy GP, Tjoa BA, Simmons SJ, Jarisch J, Bowes VA, Ragde H, Rogers M, Elgamal A, Kenny GM, Cobb OE, Ireton RC, Troychak MJ, Salgaller ML, Boynton AL.

Prostate. 1999 Jan 1;38(1):73-8.

PMID:
9973112
14.

Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides.

Tjoa BA, Simmons SJ, Bowes VA, Ragde H, Rogers M, Elgamal A, Kenny GM, Cobb OE, Ireton RC, Troychak MJ, Salgaller ML, Boynton AL, Murphy GP.

Prostate. 1998 Jun 15;36(1):39-44.

PMID:
9650914
15.

Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA).

Salgaller ML, Lodge PA, McLean JG, Tjoa BA, Loftus DJ, Ragde H, Kenny GM, Rogers M, Boynton AL, Murphy GP.

Prostate. 1998 May;35(2):144-51.

PMID:
9568678
16.

Dendritic cell-based immunotherapy of prostate cancer.

Salgaller ML, Tjoa BA, Lodge PA, Ragde H, Kenny G, Boynton A, Murphy GP.

Crit Rev Immunol. 1998;18(1-2):109-19.

PMID:
9419453
17.

Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides.

Tjoa BA, Erickson SJ, Bowes VA, Ragde H, Kenny GM, Cobb OE, Ireton RC, Troychak MJ, Boynton AL, Murphy GP.

Prostate. 1997 Sep 1;32(4):272-8.

PMID:
9288186
18.

Cancer immunotherapy for prostate cancer.

Tjoa BA, Erickson SJ, Bowes VA, Salgaller ML, Lodge PA, McLean JG, Ragde H, Kenny GM, Boynton AL, Murphy GP.

Can J Urol. 1997 Jun;4(2 Supp 1):79-82.

PMID:
12735843
19.

Measurement of prostate-specific membrane antigen in the serum with a new antibody.

Murphy GP, Tino WT, Holmes EH, Boynton AL, Erickson SJ, Bowes VA, Barren RJ, Tjoa BA, Misrock SL, Ragde H, Kenny GM.

Prostate. 1996 Apr;28(4):266-71.

PMID:
8602402
20.
22.

Sequence diversity of T cell receptor alpha chain transcripts from BALB/c thymus.

Roth ME, Tjoa BA, Schlueter CJ, Wilson ER, Lunn BC, Kranz DM.

Mol Immunol. 1992 Dec;29(12):1447-55.

PMID:
1280758

Supplemental Content

Support Center